ArticleGut2020
TGF-β2 silencing to target biliary-derived liver diseases.
Open access · hybridAbstract read
In one paragraph
Article in Gut, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- HCMV infection disrupts barrier functions and promotes epithelial-mesenchymal transition in a cholangiocyte organoid model.Nature communications · 2026Article
- Multi-omics tests identify novel shared genetic mechanisms of primary biliary cholestasis and sarcopenia.Scientific reports · 2025Article
- Primary Cilia in Hepatic Biliary Hyperplasia: Implications for Liver Diseases.Seminars in liver disease · 2025Review
- Portal Fibrosis and the Ductular Reaction: Pathophysiological Role in the Progression of Liver Disease and Translational Opportunities.Gastroenterology · 2025Review
- Mechanisms underpinning the effect of exercise on the non-alcoholic fatty liver disease: review.EXCLI journal · 2025Review
- Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications.Medical review (2021) · 2024Review
- Article
- TGFβR1 inhibition drives hepatocellular carcinoma proliferation through induction of toll-like-receptor signalling.International journal of experimental pathology · 2024Article
- Uncovering a Novel Functional Interaction Between Adult Hepatic Progenitor Cells, Inflammation and EGFR Signaling During Bile Acids-Induced Injury.International journal of biological sciences · 2024Article
- NPM promotes hepatotoxin-induced fibrosis by inhibiting ROS-induced apoptosis of hepatic stellate cells and upregulating lncMIAT-induced TGF-β2.Cell death & disease · 2023Article
- Nonalcoholic Fatty Liver Disease and Omega-3 Fatty Acids: Mechanisms and Clinical Use.Annual review of nutrition · 2023Review
- Macrophages and platelets in liver fibrosis and hepatocellular carcinoma.Frontiers in immunology · 2023Review
- Article
- Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease.JHEP reports : innovation in hepatology · 2022Review
- Antisense oligonucleotide is a promising intervention for liver diseases.Frontiers in pharmacology · 2022Review
- Review
- Multiparametric magnetic resonance imaging/magnetic resonance elastography assesses progression and regression of steatosis, inflammation, and fibrosis in alcohol-associated liver disease.Alcoholism, clinical and experimental research · 2021Article
- Orphan nuclear receptor ERRγ regulates hepatic TGF-β2 expression and fibrogenic response in CClArchives of toxicology · 2021Article
- The role of TGF-β2 in cartilage development and diseases.Bone & joint research · 2021Article
- Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders.Advanced drug delivery reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 12 institutions in 6 countries.
Anne DropmannMolecular Hepatology-Alcohol Associated Diseases, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Steven DooleyMolecular Hepatology-Alcohol Associated Diseases, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany steven.dooley@medma.uni-heidelberg.de Nadja.Meindl-Beinker@medma.uni-heidelberg.de.ORCID 0000-0002-4840-6240
Bedair DewidarMolecular Hepatology-Alcohol Associated Diseases, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Seddik HammadMolecular Hepatology-Alcohol Associated Diseases, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Tatjana DediuliaMolecular Hepatology-Alcohol Associated Diseases, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Julia WerleMolecular Hepatology-Alcohol Associated Diseases, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Vanessa HartwigMolecular Hepatology-Alcohol Associated Diseases, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Shahrouz GhafooryInstitute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany.
Stefan WoelflInstitute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany.
Hanna KorhonenIsarna Therapeutics GmbH, Munchen, Germany.
Michel JanicotIsarna Therapeutics GmbH, Munchen, Germany.
Katja WosikowskiIsarna Therapeutics GmbH, Munchen, Germany.
Timo ItzelHepatology and Clinical Bioinformatics, Department of Medicine II, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Andreas TeufelHepatology and Clinical Bioinformatics, Department of Medicine II, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.ORCID 0000-0001-7953-8927
Detlef SchuppanResearch Center for Immunotherapy, University Medical Center, Johannes Gutenberg University, Mainz, Germany.ORCID 0000-0003-3135-1359
Ana StojanovicDepartment of Immunobiochemistry, Centre for Biomedicine and Medical Technology (CBTM) and European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Adelheid CerwenkaDepartment of Immunobiochemistry, Centre for Biomedicine and Medical Technology (CBTM) and European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Stefanie NittkaInstitute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, University Hospital Mannheim, Mannheim, Germany.
Albrecht PiiperMedizinische Klinik 1, Klinikum der Goethe-Universität, Frankfurt am Main, Germany.
Timo GaiserInstitute of Pathology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.ORCID 0000-0002-6022-073X
Naiara BerazaGut Microbes and Health Institute Strategic Programme, Quadram Institute, Norwich, UK.
Malgorzata MilkiewiczDepartment of Medical Biology, Pomeranian Medical University, Szczecin, Poland.
Piotr MilkiewiczLiver and Internal Medicine Unit, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
John G BrainNIHR Applied Immunobiology and Transplant Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
David E J JonesNIHR Applied Immunobiology and Transplant Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
Thomas S WeissDepartment of Pediatrics and Juvenile Medicine, Center for Liver Cell Research, University of Regensburg Hospital, Regensburg, Germany.ORCID 0000-0003-0336-0581
Ulrich M ZangerDepartment of Molecular and Cell Biology, Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
Matthias EbertDepartment of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Nadja M Meindl-BeinkerMolecular Hepatology-Alcohol Associated Diseases, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany steven.dooley@medma.uni-heidelberg.de Nadja.Meindl-Beinker@medma.uni-heidelberg.de.ORCID 0000-0003-0211-352X
Heidelberg University · DEIsarna Therapeutics (Germany) · DENewcastle University · GBBeth Israel Deaconess Medical Center · USDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology · DEGoethe University Frankfurt · DEMedical University of Warsaw · PLPomeranian Medical University · PLQuadram Institute · GBSouth Valley University · EGTanta University · EGUniversity Hospital Regensburg · DE
Funding
Medical Research Council MR/L001489/1
Abstract
objectiveTGF-β2 (TGF-β, transforming growth factor beta), the less-investigated sibling of TGF-β1, is deregulated in rodent and human liver diseases. Former data from bile duct ligated and MDR2 knockout (KO) mouse models for human cholestatic liver disease suggested an involvement of TGF-β2 in biliary-derived liver diseases.
designAs we also found upregulated
results
conclusionsTaken together, our data suggest a new mechanistic explanation for amelioration of fibrogenesis by TGF-β2 silencing and provide a direct rationale for TGF-β2-directed drug development.
Indexed as
Cholangitis, SclerosingGene SilencingLiver CirrhosisLiver Cirrhosis, BiliaryOligonucleotides, AntisenseAnimalsATP-Binding Cassette Sub-Family B Member 4ATP Binding Cassette Transporter, Subfamily BDisease Models, AnimalDrug DiscoveryGene Expression RegulationHepatic Stellate CellsHumansMiceMice, KnockoutTransforming Growth Factor beta2ATP-Binding Cassette Sub-Family B Member 4ATP Binding Cassette Transporter, Subfamily BOligonucleotides, AntisenseTGFB2 protein, humanTgfb2 protein, mouseTransforming Growth Factor beta2cholestasisfibrosisprimary biliary cirrhosisprimary sclerosing cholangitisTGF-beta
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.